IP Library › Granted Patent US 12,569,521
Granted Patent B2
US 12,569,521 · App. 18/641,696 · Granted Mar 10, 2026

Methods and compositions for treating inflammatory skin disease with recombinant microorganisms

Inventor: Travis Michael Whitfill (Dallas, TX)
Assignee: Azitra Inc
A61K35/74A61K38/179A61K39/085A61P17/00C07K14/71A61K2035/115C07K2319/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,521
App. No.
18/641,696
Granted
Mar 10, 2026
Kind
B2
Abstract

The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.

Claims (11)

1 . A method of treating an inflammatory skin disease comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a biotherapeutic composition comprising live recombinant Staphylococcus epidermidis comprising an expression vector, wherein the expression vector, or combination of bacteria, wherein the Staphylococcus epidermidis comprises

(i) a first coding sequence comprising a nucleic acid sequence encoding a filaggrin (FLG) therapeutic polypeptide, wherein the therapeutic polypeptide consists of SEQ ID NO: 46;

(ii) a second coding sequence comprising a nucleic acid sequence encoding a cell penetrating peptide;

(iii) a third coding sequence comprising a nucleic acid sequence encoding an export signal; and

(iv) a promoter operably linked to the first coding sequence, the second coding sequence and the third coding sequence, wherein the first coding sequence, the second coding sequence and the third-coding sequence,

wherein the recombinant Staphylococcus epidermidis first coding sequence, the second coding sequence and the third-coding sequence are capable of expresses a filaggrin fusion product comprising the FLG therapeutic polypeptide.

2 . The method of claim 1 , wherein the skin disease is atopic dermatitis.

3 . The method of claim 1 , wherein the composition is applied topically.

4 . The method of claim 1 , wherein the export signal exports the filaggrin fusion product out of the recombinant bacterium.

5 . The method of claim 1 , wherein the cell penetrating peptide facilitates the entry of the filaggrin fusion product into a human keratinocyte.

6 . The method of claim 1 , wherein the first coding sequence, the second coding sequence and the third coding sequences are arranged in a single plasmid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2024
From: WHITFILL, TRAVIS MICHAEL
To: AZITRA INC.
Reel/Frame 067797/0986 →
Continuity (2)
Continuation 16121903 · Sep 5, 2018
Related Publication 20250090599A1 · Mar 20, 2025
References Cited (22)
US 10702558B2 · Munivar et al. · 2020 [cited by applicant]
US 11850267B2 · Whitfill · 2023 [cited by examiner]
US 12036248B2 · Munivar · 2024 [cited by examiner]
US 20110236325A1 · Mitchell et al. · 2011 [cited by applicant]
US 20130018000A1 · Stout · 2013 [cited by applicant]
US 20160199513A1 · Bancel et al. · 2016 [cited by applicant]
US 20160220701A1 · March et al. · 2016 [cited by applicant]
US 20170051260A1 · Bermudes et al. · 2017 [cited by applicant]
US 20190298780A1 · Whitfill · 2019 [cited by applicant]
CN 106062000A · 2016 [cited by applicant]
JP 2017518370A · 2017 [cited by applicant]
WO 2009112301A2 · 2009 [cited by applicant]
WO 2015117021A1 · 2015 [cited by applicant]
WO 2015184134A1 · 2015 [cited by applicant]
WO 2017136652A1 · 2017 [cited by applicant]
Sohn et al. Mount Sinai J. of Medicine 78:730-739, 2011. [cited by examiner]
U.S. Appl. No. 16/121,903, filed Sep. 5, 2018, 2019-0298780, Published. [cited by applicant]
Boguniewicz et al., Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. Jul. 2011;242(1):233-46. [cited by applicant]
Ma et al., Cell-penetrating peptides mediated protein cross-membrane delivery and its use in bacterial vector vaccine. Fish Shellfish Immunol. Jul. 2014;39(1):8-16. [cited by applicant]
NCBI Accession No. NP_002007, filaggrin [ [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2018/049477, dated Jan. 16, 2019, 10 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2018/049477, dated Mar. 10, 2020, 7 pages. [cited by applicant]